Korean J Med.  2008 Feb;74(2):176-180.

Intravenous Anti-D immunoglobulin treatment of adult chronic immune thrombocytopenic purpura (ITP)

Affiliations
  • 1Department of Internal Medicine, Seoul Veterans Hospital, Seoul, Korea. seog@e-bohun.or.kr
  • 2Department of Internal Medicine, Bundang Cha Hospital, College of Medicine, Pochon Cha University, Bundang, Korea.
  • 3Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Abstract

BACKGROUND/AIMS: Immune thrombocytopenic purpura (ITP) is an autoimmune disease that is mediated by anti-platelet antibodies. Based on the pathogenesis of ITP we evaluated the efficacy of intravenous anti-D immunoglobulin for adult chronic ITP.
METHODS
Fourteen patients (4 without splenectomy and 10 with splenectomy) with refractory chronic ITP were treated with 50-70 microgram/kg of intravenous anti-D immunoglobulin only once. Treatment effects were evaluated by measuring the platelet counts and hemoglobin levels.
RESULTS
Five patients (36%) showed a response; improvement in the platelet count lasted for on average 7 days (range: 2~24 days). There were no serious adverse effects.
CONCLUSION
Anti-D immunoglobulin, which is associated with an Fc receptor blockade, appeared to be safe and effective for the treatment of adults with chronic ITP. Further studies are needed to confirm these findings and define further potentially effective treatment protocols with intravenous anti-D immunoglobulin.

Keyword

Chronic immune thrombocytopenic purpura; Fc receptor blockade; Anti-D-immunoglobulin

MeSH Terms

Adult
Antibodies
Autoimmune Diseases
Clinical Protocols
Hemoglobins
Humans
Immunoglobulins
Isoantibodies
Platelet Count
Purpura, Thrombocytopenic, Idiopathic
Receptors, Fc
Rho(D) Immune Globulin
Splenectomy
Antibodies
Hemoglobins
Immunoglobulins
Isoantibodies
Receptors, Fc
Rho(D) Immune Globulin
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr